Outcome MeasureWell-being

PTGI

Post-Traumatic Growth Inventory

4 Papers in Blossom

About This Instrument

The Post-Traumatic Growth Inventory (PTGI) is a 21-item self-report measure developed by Richard Tedeschi and Lawrence Calhoun to assess positive psychological changes experienced as a result of struggling with highly challenging life circumstances. Each item is rated on a 0–5 scale (0 = did not experience, 5 = experienced to a very great degree), yielding total scores from 0 to 105. The PTGI measures five domains of growth: relating to others, new possibilities, personal strength, spiritual change, and appreciation of life. In psychedelic-assisted therapy research, the PTGI is used to capture whether treatment facilitates meaningful positive changes beyond mere symptom reduction, aligning with the transformative experiences often reported by participants. Higher scores indicate greater perceived post-traumatic growth.

Clinical Thresholds

0105
Low growth
Score 034
Moderate growth
Score 3569
High growth
Score 70105

Outcome Data Across Studies

Reported results for PTGI across 4 studies with quantitative data.

Outcome data across 9 study arm–timepoint observations
SD
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
2018Secondary
Full dose(experimental)0318.0
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
2018Secondary
Full dose(experimental)60352.0
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
2020Secondary
MDMA-assisted therapy(experimental)01358.119.9
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
2020Secondary
MDMA-assisted therapy(experimental)301371.018.80.040
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
2020Secondary
Placebo with therapy(inactive)0564.019.1
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
2020Secondary
Placebo with therapy(inactive)30561.424.90.040
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil
2021Secondary
MDMA-assisted psychotherapy(experimental)0318.013.9
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil
2021Secondary
MDMA-assisted psychotherapy(experimental)112370.713.6
Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation
2025Exploratory
Psilocybin-assisted treatment program(experimental)74463.018.6

Papers Using PTGI

Quick Facts

Full Name
Post-Traumatic Growth Inventory
Domain
Well-being
Papers Indexed
4
Score Range
0105
Interpretation
Higher = better
Unit
points
All Measures